PMID: 3214941May 1, 1988Paper

Outcome following standardized 185 MBq dose 131I therapy for Graves' disease

Clinical Endocrinology
A B WatsonT Rogers

Abstract

The clinical outcome of 199 patients with Graves' disease treated with standardized 185MBq 131I therapy doses has been analysed. Most patients were controlled with antithyroid drugs prior to the 131I therapy, and also received antithyroid drugs for several months following 131I. The median follow-up period was 5.5 years. The single 185MBq 131I dose successfully treated 72.4% of patients. The 1, 2 and 5 year hypothyroid figures were 15.5%, 19.3% and 27.3%, respectively. Previous thyroidectomy was associated with an increased hypothyroid rate. Retreatment was required by 25.6%, with 3.5% requiring more than two 131I doses. Discriminant analysis of pretreatment variables suggests that patients with large goitres or severe disease (serum T3 greater than 10nmol/l) should be treated with higher doses of 131I.

References

Mar 20, 1976·Lancet·J G TurnerT G Rogers
Jul 1, 1979·Journal of Endocrinological Investigation·B E BrownlieT G Rogers
Apr 1, 1976·International Journal of Nuclear Medicine and Biology·D I ArmstrongJ G Turner
Jun 14, 1986·Lancet·G HennemannK Sankaranarayanan
Feb 1, 1986·Clinical Endocrinology·A W Goolden, J S Stewart
Dec 1, 1986·Annals of Internal Medicine·G D Graham, K D Burman
May 1, 1985·Clinics in Endocrinology and Metabolism·K E Halnan
Oct 20, 1973·Lancet·J L Parker, D H Lawson
Jan 21, 1967·British Medical Journal·R N Smith, G M Wilson
Apr 1, 1982·Acta Endocrinologica·H BliddalK Siersbaek-Nielsen
Aug 16, 1984·The New England Journal of Medicine·V SridamaL J DeGroot
Jan 1, 1956·The British Journal of Radiology·W K SINCLAIRL F LAMERTON

❮ Previous
Next ❯

Citations

Apr 9, 1998·Baillière's Clinical Endocrinology and Metabolism·J A Franklyn
Jun 16, 1994·The New England Journal of Medicine·J A Franklyn
May 5, 2005·Cancer Biotherapy & Radiopharmaceuticals·Mariano GrossoGiuliano Mariani
May 5, 2009·Journal of Endocrinological Investigation·C RegalbutoV Pezzino
Mar 11, 2008·World Journal of Surgery·Peter StålbergPer Hellman
Nov 4, 2004·Clinical Endocrinology·Saara MetsoJorma Salmi
Sep 1, 1995·Clinical Endocrinology·A E JarløvJ M Hansen
Jan 1, 1991·Clinical Endocrinology·J A FranklynM C Sheppard
Sep 1, 1991·Clinical Endocrinology·J J Farrar, A D Toft
May 1, 2004·Endocrine Journal·Yasuyo YamashitaNobuoki Kohno
Feb 7, 2006·The Journal of Surgical Research·Chris M Schüssler-FiorenzaHerbert Chen
Sep 27, 2014·Acta Medica (Hradec Králové)·Jitka CepkováJiří Doležal
Feb 19, 2016·The Cochrane Database of Systematic Reviews·Chao MaSuyun Chen
Jan 8, 2019·Nuclear Medicine Communications·Sarameth Thou, Sobhan Vinjamuri
Sep 21, 2004·Oncogene·Julie LessardGuy Sauvageau
Dec 21, 2004·Oncogene·Georgina LangKathleen Weston
Jul 5, 2007·The Journal of Clinical Endocrinology and Metabolism·Vinko Markovic, Davor Eterovic
Aug 15, 2001·The Journal of Clinical Endocrinology and Metabolism·A AllahabadiaJ A Franklyn
Sep 26, 2001·BMC Nuclear Medicine·Suhail AR DoiKamal AS Al-Shoumer
Jun 1, 1992·The Journal of International Medical Research·A ZainiB H Khoo
Jul 26, 2016·International Journal of Endocrinology·Jade A U TamateaMarianne S Elston

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.